Stockwinners Market Radar for June 02, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:15 EDT ABM CEO Salmirs sells 14,983 common shares - In a regulatory filing, ABM Industries president and CEO Scott Salmirs disclosed the sale of 14,983 common shares of the company on June 2 at a price of $45.4443 per share.

17:43 EDT Zimmer Energy Transition announces redemption of public shares - Zimmer Energy Transition announced that it will redeem all of its outstanding shares of common stock that were included in the units issued in its initial public offering, effective as of the close of business on June 16, 2023, as the company will not consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation. The estimated per-share redemption price for the public shares will be approximately $10.25. The public shares will cease trading as of the close of business on June 15, 2023. As of the close of business on June 16, 2023, the public shares will be deemed cancelled and will represent only the right to receive the redemption amount.

17:36 EDT S&P DJI announces changes to S&P 600 at open on 6/20 - Artisan Partners Asset Management (APAM), California Resources(CRC), CarGurus (CARG), Moelis & Co. (MC), Phillips Edison & Company (PECO), Schrodinger (SDGR), and UFP Technologies (UFPT) will replace LendingTree (TREE), Tredegar (TG), Inogen (INGN), Douglas Elliman (DOUG), FARO Technologies (FARO), Cara Therapeutics (CARA) and Big Lots (BIG) in the S&P SmallCap 600.

17:19 EDT Dish to replace Cutera in S&P 600 at open on 6/20

17:18 EDT Palo Alto Networks to replace Dish in S&P 500 at open on 6/20

17:01 EDT LoanDepot names Hayes CFO, consolidates LDI Digital into existing channels - As part of its previously announced Vision 2025 plan, LoanDepot announced organizational changes expected to improve operational efficiency, simplify the company's leadership structure, and move certain key executive leadership positions to its Orange County, Calif. headquarters. David Hayes, a senior finance executive with over 25 years of financial management, treasury, corporate finance, and mortgage industry experience, has been appointed Chief Financial Officer, effective June 26, 2023. Hayes, who will be based out of the company's headquarters in Irvine, will be responsible for managing loanDepot's financial functions, including its accounting, treasury, tax, corporate finance, and investor and lender relations activities. He joins loanDepot from CoreLogic, Inc., where he most recently served as Executive, Finance and Treasurer. Hayes succeeds Patrick Flanagan, who will be departing the company after a transition period. loanDepot will also consolidate LDI Digital (including mellohome) into its existing production channels, under the leadership of LDI Mortgage President Jeff Walsh. This action is expected to further integrate the company's digital products and unify its customer offerings. As a result of this organizational change, LDI Digital President Zeenat Sidi will be transitioning out of the organization. In addition, the company will further streamline its management structure with the departures of Chief Accounting Officer Nicole Carrillo and Chief Human Resources Officer Kevin Tackaberry, who each will be leaving after a transition period.

16:45 EDT Best Buy CEO Barry sells 17,382 common shares - In a regulatory filing, Best Buy CEO Corie Barry disclosed the sale of 17,382 common shares of the company on June 1 at a price of $71.823 per share.

16:31 EDT Phunware says Troy Reisner to succeed Matt Aune as CFO - Phunware announced the appointment of Troy Reisner as CFO, effective June 2. Reisner will succeed Matt Aune and will become a member of the company's executive management team, reporting to Russ Buyse, the company's CEO. Matt Aune will fully transition into his role as an advisor and continue to support the company through December 31, 2023. Most recently, Reisner served as CFO of Keystone Tower Systems where he managed the finance division for nearly four years.

16:22 EDT CCC Intelligent Solutions exec Herb sells 97,459 common shares - In a regulatory filing, CCC Intelligent Solutions chief financial and administrative officer Brian Herb disclosed the sale of 97,459 common shares of the company on June 1 at a price of $11.0787 per share.

16:19 EDT Disney sees $1.5B impairment charge in Q3 over DTC content removal - According to a regulatory filing, as previously announced, The Walt Disney Company is in the process of reviewing content, primarily on its direct-to-consumer services, for alignment with a strategic change in approach to content curation and as a result is removing certain content from its platforms. On May 26, 2023, the company removed certain produced content from its DTC services. As a result, the company will record a $1.5B impairment charge in its fiscal third quarter financial statements to adjust the carrying value of these content assets to fair value. The company is continuing its review and currently anticipates additional produced content will be removed from its DTC and other platforms, largely during the remainder of its third fiscal quarter. As a result, the company currently estimates it may incur further impairment charges of up to approximately $0.4B related to produced content. The company does not expect any material cash expenditures in connection with the impairment charges related to produced content. In addition, the company may terminate certain license agreements for the right to use content on its platforms, which would result in the removal of licensed content from its platforms and lead to impairment and/or contract termination charges as well as cash payments. The company currently expects that any such charges and payments related to licensed content would be meaningfully less than the impairment charges related to produced content.

16:07 EDT Insulet director Petrovic sells 15,000 common shares - In a regulatory filing, Insulet director Shacey Petrovic disclosed the sale of 15,000 common shares of the company on June 1 at a price of $271.56 per share.

16:01 EDT Blue World Acquisition announces extension of deadline for business combination - Blue World Acquisition announced that, in order to extend the date by which the company must complete its initial business combination from June 2, 2023 to July 2, 2023, an aggregate of $194,324, representing $0.0295 per public share of the company, was deposited into its trust account. In connection with this extension, the company issued an unsecured promissory note to Blue World Holdings Limited, the sponsor of the company, to evidence the payment of the Extension Fee.

15:36 EDT Geron reports IMerge Phase 3 results at ASCO - Geron announced a presentation reporting durable continuous transfusion independence with imetelstat, the company's first-in-class telomerase inhibitor, in IMerge Phase 3 lower risk MDS patients. These data were presented today at the American Society of Clinical Oncology, or ASCO, Annual Meeting in Chicago, the company reported. IMerge Phase 3 enrolled lower risk MDS patients who were relapsed after, refractory to, or ineligible for erythropoiesis stimulating agent treatment and were transfusion dependent, defined as requiring at least four units of packed red blood cells over an eight-week period. The ASCO presentation reported IMerge Phase 3 results with a data cut-off of October 2022, the same for top-line results reported in January 2023. The primary endpoint of 8-week transfusion independence was met with high statistical significance for imetelstat-treated patients vs. placebo. Of the imetelstat 8-week responders, 83% had a single continuous TI period. Highly statistically significant durable transfusion independence for 8-week TI responders was achieved with a median TI duration approaching one year for imetelstat, compared to approximately 13 weeks for placebo. The key secondary endpoint of 24-week TI was also met with high statistical significance for imetelstat-treated patients vs. placebo. "The presentation at ASCO of our IMerge Phase 3 data highlighted the meaningful longer-term duration of transfusion independence with imetelstat compared to placebo, as well as significantly higher rates of TI across MDS subgroups, greater reductions in transfusion units and sustained increases in hemoglobin levels. With our U.S. New Drug Application based on these data on track to be submitted to the FDA this month, I look forward to the day when imetelstat could be available for lower risk MDS patients in the first half of 2024," said Faye Feller, M.D., Executive Vice President, Chief Medical Officer of Geron.

15:06 EDT Chijet Motor announces start of trading on Nasdaq - Chijet Motor, a developer of next-generation electric vehicles, was officially listed on Nasdaq on June 2, under the ticker symbol "CJET," the company announced. "Chijet is a new energy vehicle group company with main operating entities of Shandong Baoya New Energy Vehicle Co., Ltd. and its holding subsidiary, FAW Jilin Automobile Co., Ltd. The Company combines the innovative vitality of new car-making design and engineering forces with mature scale vehicle production capacity, and is committed to building Chijet into a scenario-driven, technology-led and, experience-based, new energy vehicle enterprise with global market operation capability. The company's vision is to provide high quality and cost-effective new energy vehicle products and services to more than 80% of mass consumers in China, as well as in the future to consumers in Southeast Asia, America, GCC and other developing countries, and provide an easy and pleasant driving experience to general consumers in the intelligent era. Chijet will integrate high quality R&D and engineering resources to form a China-led and globally linked international product creation system to continuously meet the R&D needs of passenger cars, commercial vehicles, advanced technologies and key components... In the next few years, with the launch of its FB77, a cost-effective pure electric sedan, and its R9 PHEV hybrid SUV, Chijet's plans include development of more than a dozen new products including its FV20, FB21 and FB31 vehicles, among others," the company stated.

14:22 EDT Nintendo announces 'Everybody 1-2 Switch,' out June 30 - Last night, Nintendo announced that party game "Everybody 1-2 Switch," a sequel to 2017's "1-2 Switch," will release exclusively on Switch on June 30. Reference Link

13:08 EDT Alpine 4 Holdings appoints Christopher Meinerz as CFO - On May 30, 2023, the Board of Directors of Alpine 4 appointed Christopher Meinerz to serve as CFO of the Company. Prior to joining the Company, Mr. Meinerz has held the title of CFO, COO, and CCO for several different public and private companies.

13:05 EDT Blue Bird appoints Britton Smith as president - Blue Bird Corporation announced the appointment of Britton Smith to president, effective July 1, 2023. Phil Horlock, Blue Bird president and CEO, will continue to hold the role of CEO after Smith's appointment takes effect. Smith joined Blue Bird in March 2022 as Senior Vice President of Electrification and Chief Strategy Officer. He will continue to lead this key business initiative while taking on additional responsibilities across the company which will reinforce Blue Bird's industry leadership in low- and zero-emissions student transportation.

13:02 EDT Baker Hughes reports U.S. rig count down 15 to 696 rigs

12:38 EDT GAMCO sends letter to Telephone and Data Systems - GAMCO Asset Management, an affiliate of GAMCO Investors, and certain other affiliates own, on behalf of their clients, approximately 4.3% of the outstanding common shares of Telephone and Data Systems. GAMCO sent a letter to the company's President and CEO, saying in part: "We have been following TDS for nearly four decades. We currently own 4.5 million shares of TDS common stock for clients. We did not share any concerns when the Company changed the voting structure some twenty years ago. While we were concerned about the press articles discussing the bid by a third party at over $100 a share, we have put that in the background. We are all committed to serving the communities but in light of the increases in cost of capital, we are also committed to do it efficiently. However, with the current collapse of the stock we need to again examine what is the appropriate allocation of capital and how to grow the intrinsic value and allow it to surface. We are considering the probability of nominating Directors at the next Shareholder meeting. While we have reviewed suggestions on numerous occasions in the past, we will bring these to the table again in light of the extraordinarily poor performance and the lack of focus as a result of TDS' ownership of US Cellular and other dynamics. It is hard to accept that this condition exists. A change in tactics has to be examined and pursued."

12:18 EDT Theratechnologies receives FDA agreement for amended trial protocol - Theratechnologies announced that the U.S. Food and Drug Administration has agreed to the Company's amended protocol for the Phase 1 clinical trial of sudocetaxel zendusortide, an investigational, first-in-class peptide-drug conjugate that targets the sortilin receptor and expedites the internalization and delivery of a cytotoxic payload directly into cancer cells. Today's announcement also marks the lifting of the FDA's partial clinical hold on the Phase 1 trial, following the Company's voluntary pause of patient recruitment in December 2022. In May 2023, Theratechnologies filed the amended trial protocol, which is designed to improve the therapeutic window of sudocetaxel zendusortide and extend its duration of therapy. The updates include a change in the frequency of administration to weekly dosing and a narrowing of the patient population to focus on those with high-grade serous ovarian cancer, including high-grade peritoneal or fallopian tube cancer, or high-grade endometrioid cancer - a population in which preliminary efficacy has been observed thus far. Patient selection has also been refined to focus on those who are less heavily pretreated, with no more than one taxane failure and a maximum of eight prior cancer treatment regimens. The amended study will be a modified 6+6 design with two different dosing regimens that are within the efficacious range for sudocetaxel zendusortide: 1.75 mg/kg on days 1, 8, and 15 of a 28-day cycle and 2.5 mg/kg on the same schedule. A minimum of six patients will be enrolled at the 1.75 mg/kg dose followed by an observational period of three months to assess dose-limiting toxicity. If deemed safe, the trial will enroll an additional six patients at the 2.5 mg/kg dose. Following a second three-month observational period, four more patients will be enrolled at the higher dose, for a total of 16 patients in Part 3 of the trial. The amendments also include an option for a basket expansion stage that will comprise patients with selected, difficult-to-treat tumor types in which sudocetaxel zendusortide has shown activity. Researchers are presenting early results from Part 1 and Part 2 of the multicenter, open-label, Phase 1 trial of sudocetaxel zendusortide at a poster session at the 2023 annual meeting of the American Society of Clinical Oncology on Saturday June 3, in Chicago. Those preliminary safety and efficacy data, which can be found here, informed the FDA-approved amended protocol.

12:06 EDT AstraZeneca says Imfinzi plus chemotherapy showed clinical benefit in trial - AstraZeneca reports "positive high-level results" from a planned interim analysis of the MATTERHORN Phase 3 trial, which showed treatment with AstraZeneca's Imfinzi added to standard-of-care FLOT neoadjuvant chemotherapy demonstrated a "statistically significant and clinically meaningful improvement" in the key secondary endpoint of pathologic complete response, or pCR, versus neoadjuvant chemotherapy alone for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction, or GEJ, cancers. The trial will continue as planned to assess EFS and overall survival to which the trial team, investigators and participants remain blinded. The safety and tolerability of adding Imfinzi to neoadjuvant FLOT chemotherapy was consistent with the known profile of this combination and did not decrease the number of patients able to undergo surgery versus chemotherapy alone. These data will be shared with health authorities and presented at a forthcoming medical meeting. Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "These early results from MATTERHORN support harnessing the immune system together with chemotherapy and surgery as a new treatment approach to improve outcomes for patients with earlier stages of gastric and gastroesophageal junction cancers. These findings reinforce our focus on delivering novel Imfinzi-based treatments that have the potential to redefine care for patients with gastrointestinal cancers."

12:00 EDT Guidewire falls -13.7% - Guidewire is down -13.7%, or -$11.33 to $71.51.

12:00 EDT SentinelOne falls -36.6% - SentinelOne is down -36.6%, or -$7.58 to $13.14.

12:00 EDT Chemours rises 23.1% - Chemours is up 23.1%, or $6.27 to $33.38.

11:53 EDT Pennsylvania AG files complaint against DuPont, affiliates over PFAS - Pennsylvania Attorney General Michelle Henry announced that the Office of Attorney General has taken action against DuPont (DD) and two other chemical companies - Chemours (CC) and Corteva (CTVA) - for the continued manufacturing and distribution of products containing "forever chemicals." "DuPont, Chemours, and Corteva companies caused widespread environmental damages due to the PFAS, or 'forever chemicals,' contained in products such as AFFF, a foam substance used by firefighters in training exercises. The Office of Attorney General alleges the companies are in violation of Pennsylvania's Consumer Protection Law," the AG stated. The Office of Attorney General represents the Commonwealth and Department of Environmental Protection in filing a complaint in Pennsylvania Commonwealth Court, seeking restitution, civil penalties, and other costs to be determined. Reference Link

11:40 EDT Sound Point Acquisition I will not consummate business combination - Sound Point Acquisition Corp I announced that, because the Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association, the Company intends to liquidate and dissolve in accordance with the provisions of the Amended Articles, effective as of June 4, 2023, and will redeem all of the outstanding Class A ordinary shares that were included in the units issued in its initial public offering, at an anticipated per-share redemption price of approximately $10.63. As of the close of business on June 4, 2023, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount. In order to provide for the disbursement of funds from the trust account, the Company will instruct the trustee of the trust account to take all necessary actions to liquidate the securities held in the trust account. The proceeds of the trust account will be held in a trust operating account at J.P. Morgan Chase Bank, N.A. while awaiting disbursement to the holders of the Public Shares. Record holders will receive their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company's transfer agent. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after June 4, 2023. The Company's sponsor, officers and directors have agreed to waive their redemption rights with respect to their outstanding Class B ordinary shares issued prior to the Company's initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless.

11:30 EDT GM CEO says Tesla has cost advantage in EVs over other car makers

11:23 EDT Deere appoints CTO Jahmy Hindman as SVP - Deere & Company announced that its Board of Directors elected Jahmy Hindman senior vice president in addition to his current position as chief technology officer, which he has held since 2020. This move reflects the vital role of technology in the success of customers' and Deere's operations. Additionally, the following leadership changes will take place later this year: Mark von Pentz, president, Worldwide Ag & Turf, Small Ag & Turf, Regions 1 & 2, will continue in his present position until November 1, 2023, at which time he will become senior advisor, Office of the Chairman, until his anticipated retirement early in 2024. Deanna Kovar, vice president, Production Systems, Production and Precision Ag, will take on additional responsibilities in Small Ag & Turf and will fully transition to the role of president, Worldwide Ag & Turf, Small Ag & Turf, Regions 1 & 2, on November 1, 2023.

11:19 EDT General Motors CEO says company takes every EV competitor 'seriously' - Says takes every EV competitor "seriously." Says scale matters in this business. Sees consolidation in EV space. Says number of EV startups, especially in China, is "not sustainable." Says looking at "many opportunities" in partnerships in EV. Says in "first lap of a long race" in EV battery technology. Comments taken from Bernstein 39th Annual Strategic Decisions Conference.

10:56 EDT Akebia subsidiary settles patent litigation with Zydus over generic Auryxia - In a regulatory filing earlier, Akebia Therapeutics disclosed that on May 30, Keryx Biopharmaceuticals, a wholly owned subsidiary of Akebia, and Panion & BF Biotech entered into a settlement and license agreement with Zydus. This settlement resolves patent litigation brought by Keryx and Panion in response to Zydus' Paragraph IV certification notice letter regarding their Abbreviated New Drug Application, or "ANDA," seeking approval to market a generic version of Auryxia tablets prior to the expiration of the applicable patents. "Pursuant to the terms of the agreement and, consistent with Keryx's prior ANDA settlements with Teva Pharmaceuticals USA, Inc., Watson Laboratories, Inc., Par Pharmaceutical, Inc., Lupin Atlantis Holdings SA, Chemo Research S.L., and Mylan Pharmaceuticals Inc., Keryx and Panion will grant Zydus a license to market a generic version of Auryxia in the United States beginning on March 20, 2025, subject to U.S. Food and Drug Administration approval, or earlier under certain circumstances customary for settlement agreements of this nature. Additionally, in accordance with the agreement, the parties will terminate all ongoing litigation among Keryx, Panion and Zydus regarding Auryxia patents pending in the United States District Court for the District of Delaware. The agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. Keryx and Panion have now entered into settlement and license agreements resolving all patent litigation proceedings brought by Keryx and Panion in response to ANDAs filed by third parties seeking approval to market generic versions of Auryxia tablets prior to the expiration of the applicable patents," the filing stated.

10:00 EDT Guidewire falls -7.9% - Guidewire is down -7.9%, or -$6.56 to $76.28.

10:00 EDT SentinelOne falls -31.9% - SentinelOne is down -31.9%, or -$6.61 to $14.11.

10:00 EDT Big Lots rises 23.2% - Big Lots is up 23.2%, or $1.13 to $6.00.

09:47 EDT Tilly's falls -7.9% - Tilly's is down -7.9%, or -58c to $6.80.

09:47 EDT SentinelOne falls -35.1% - SentinelOne is down -35.1%, or -$7.28 to $13.44.

09:47 EDT Chemours rises 15.3% - Chemours is up 15.3%, or $4.14 to $31.25.

09:45 EDT Texas State University signs contract for Knightscope K1 Blue Light E-Phones - Knightscope announced that it received a new contract for 13 K1 Blue Light E-Phones from Texas State University.

09:41 EDT SunCar Technology Group Inc trading resumes

09:39 EDT FirstEnergy completes nine-mile transmission line upgrade in Ohio - American Transmission Systems has upgraded nine miles of a high-voltage power line in Carroll and Harrison counties in Ohio to strengthen the regional transmission system. The second phase of a larger 64-mile transmission line project, the rebuilt segment will enhance service reliability for Ohio Edison customers, improve system resiliency and accommodate increasing customer demand for electricity in the future. The approximately $50M project involved replacing 57 wood pole structures with new steel structures and installing larger wires that can carry more electrical load.

09:37 EDT Investors urges Cano Health shareholders to withhold support for Muney, Rivera - Elliot Cooperstone, Lewis Gold and Barry Sternlicht released a letter to Cano Health stockholders: The company said, "The three of us - Elliot Cooperstone, Lewis Gold and Barry Sternlicht - hold an approximately 35% equity stake in Cano Health, making our Group the largest stockholder of the Company. The three of us served on Cano's Board of Directors until this spring, when it became clear to us that Chief Executive Officer Dr. Marlow Hernandez and his boardroom allies had tuned out our consistent calls for better corporate governance, enhanced disclosure practices, improved capital allocation and financial controls, and a refined strategy. We contend Dr. Hernandez and Cano's management-friendly directors demonstrated unconscionable levels of arrogance and intransigence by forming a "Shadow Board" that excluded us. This took place despite their ardent championing of actions that precipitated Cano's stock price declining by more than 90% since the Company went public in June 2021. Rather than allow Cano's current leadership to continue running the organization into the ground, we have begun a campaign - for the benefit of all stockholders - to turn around the Company from the outside. We have sought to lay a foundation for this turnaround over the past two months by doing the following: Filing proxy materials to solicit WITHHOLD votes against the two management-friendly members of the Board up for re-election at the 2023 Annual Meeting of Stockholders on June 15, 2023: Dr. Alan Muney, Chair of Cano's Compensation Committee, and Kim Rivera, Chair of Cano's Nominating & Corporate Governance Committee. We urge you to send a clear message at this year's Annual Meeting by voting WITHHOLD on Proposal 1 on any proxy card received. Submitting a notice to Cano to nominate two highly qualified, independent candidates - Joseph Berardo, Jr. and Guy P. Sansone - for election to the Board at the Annual Meeting. Messrs. Berardo and Sansone possess significant healthcare services experience as well as backgrounds in corporate governance, capital allocation, transactions and strategic planning. Submitting a proposal to Cano to give stockholders the opportunity to vote on the removal of Dr. Hernandez from the Board for cause at the Annual Meeting. Urging Cano's Board to voluntarily reopen the window for nominating director candidates and making business proposals at the upcoming Annual Meeting - a seemingly logical step given the extraordinary circumstances at the Company. Ultimately filing a lawsuit against Cano in the Delaware Court of Chancery to compel the Company to reopen the window for nominating director candidates and making business proposals at the upcoming Annual Meeting. Your ability to vote on the election of our two director candidates and the Removal Proposal is dependent on the success of this lawsuit. A ruling is expected early this month. The fact that three of us are investing our own capital, resources and time into this campaign should reinforce that we are committed to initiating a turnaround and are squarely aligned with you. As outlined in the subsequent sections of this letter, we have a deep understanding of the challenges at Cano and possess a clear vision for turning around the Company. We believe our ideas represent a stark contrast to the "state of denial" that Dr. Hernandez and his close associates seem to be operating in...We will continue to press for Board and leadership changes following the Annual Meeting to help initiate an enduring turnaround that can maximize value for all Cano stakeholders. In the meantime, we urge stockholders to vote WITHHOLD on Proposal 1 on any proxy card received.

09:31 EDT SunCar Technology Group Inc trading halted, volatility trading pause

09:18 EDT Ford reports May U.S. sales up 10.7% to 170,933 vehicles - Ford reports May U.S. sales were up 10.7% from the same month of last year to 170,933 vehicles, including 5,444 electric vehicles, 10,715 hybrid vehicles and 154,774 internal combustion vehicles. Reference Link

09:15 EDT Carvana down 5% after canceling exchange offer for up to $1B of notes - Shares of Carvana are down 75c, or 5%, to $15.05 in pre-market trading after the company announced the expiration and termination of its previously announced offers to exchange its outstanding existing notes for up to an aggregate principal amount of $1B of new 9.0%/12.0% Cash/PIK Toggle Senior Secured Second Lien Notes due 2028 issued by the company.

09:05 EDT CleanSpark mined 609 bitcoin in May - CleanSpark released its unaudited bitcoin mining and operations update for the month ending May 31, 2023. "We achieved a significant milestone during the month of May," said Zach Bradford, CEO. "Not only do we continue to increase the amount of bitcoin in our treasury, but we also surpassed $100 million in revenue for our fiscal year to date. Importantly, we achieved this milestone with the bulk of our expansion expected to come later this year." May Bitcoin Mining Update: Bitcoin mined in May: 609; CY2023 bitcoin mined: 3,004; Total BTC holdings as of May 31: 451; Total BTC converted for operations and growth in May: 471; Currently deployed fleet of about 67,196 latest-generation bitcoin miners with a hashrate of 6.7 EH/s

09:04 EDT SciSparc announces results of its Phase IIa trial of SCI-110 - SciSparc announced positive topline results from its investigator-initiated Phase IIa trial at the Sophie & Abraham Stuchynski Israeli Alzheimer's Medical Center, IMCA, which suggest that the Company's proprietary SCI-110 is safe and tolerable while significantly improving agitation symptoms over time in elderly population with Alzheimer disease and agitation. This Phase IIa clinical trial was an open label trial, which included 18 patients diagnosed with AD and agitation, to evaluate the safety, tolerability, and efficacy trends of twice daily oral administration of SCI-110. Results showed that the trial met its primary endpoints of the number of drop-out subjects' due to poor tolerability and the number of trial treatment related adverse events, with no SCI-110 related safety issues observed and no dropouts from the trial due to trial medication. Specifically, SCI-110 did not cause delirium, oversedation, hypotension or falls. In addition, analysis of the trial results showed that the trial also met its secondary end point of change from baseline to end of treatment in agitation measured by the Cohen Mansfield Agitation Inventory where out of the fifteen patients treated with SCI-110 at least two consecutive times during the trial, thirteen of them at doses ranging between 7.5mg-12.5mg/day showed amelioration in agitation with no need to use rescue medication to control agitation. CMAI is a standard measure for measuring agitation in people with dementia. The trial showed that these subjects had amelioration in agitation from baseline. This resulted in an average reduction of 23% across the entire sample. In the exploratory end points, a decrease in eating and feeding difficulties was shown in 11 patients out of the 15 patients treated at least two consecutive times during the trial as measured by the Edinburgh Feeding Evaluation in Dementia Scale, although the increase was not significant. No effect from the treatment was observed on cognitive measurements and sleep quality, as measured by the Mini Mental State Exam and by the and the Sleep Disorder Inventory, respectively.

08:57 EDT Clover Leaf Capital, Kustom Entertainment enter business combination agreement - Digital Ally, Inc. (DGLY) and Clover Leaf Capital Corp. (CLOE) announced that Kustom Entertainment, a wholly-owned subsidiary of Digital Ally focused on live events, concert production and ticketing, and CLOE have entered into a merger agreement. The transaction is expected to provide Kustom Entertainment with the ability to be a stand-alone entity with a focus and mission to own and produce events, festivals, and entertainment alongside its evolving primary and secondary ticketing technologies. Digital Ally will remain an independent public company following the merger. Kustom Entertainment is comprised of TicketSmarter and Kustom 440, both currently wholly owned subsidiaries. Both TicketSmarter and Kustom 440 will combine their management teams and focus on concerts, entertainment and garnering additional ticketing partnerships in 2023 and beyond. Kustom 440 and TicketSmarter will use their existing sponsorships and sports property partnerships to develop alternative entertainment options for consumers. The combined company will be known as Kustom Entertainment and will operate under the same management team as Kustom Entertainment, Inc. which is currently led by Stanton Ross, the current CEO of Digital Ally. The transaction contemplates an equity value of $125M for Kustom Entertainment, Inc. The combined company is expected to have an implied initial pro forma equity value of approximately $222.2M, with the proposed business combination expected to provide approximately $18.1M in gross proceeds from the cash held in trust by CLOE, assuming no redemptions. Additionally, Digital Ally will distribute to its shareholders 15% of the shares obtained in Kustom Entertainment immediately following the closing of the merger and intends to distribute the balance of such shares following a six-month lock-up period. The transaction has been approved by the Boards of Directors of both Digital Ally and CLOE and is subject to approval by the stockholders of CLOE and other customary closing conditions. Digital Ally, as the sole holder of Kustom Entertainment common stock, has approved the transaction.

08:50 EDT Silo Pharma joins Webull Corporate Communications Platform - Silo Pharma is now actively participating on the Webull Corporate Communications Service Platform. The Silo Pharma portal on Webull offers an additional channel for direct investor communication and audience engagement, including Q&A.

08:41 EDT Tingo Mobile advances loan facility to All Farmers Association of Nigeria - Tingo Group announced has provided a 3 Billion Naira loan facility to the All Farmers Association of Nigeria for the primary purpose of cultivating 3,000 hectares of new farming land for rice and wheat production. AFAN will also utilize part of the loan facility to accelerate the onboarding of its warehouses to the Tingo Mobile partnership with Prime Commodity Exchange and AFAN as part of its target to achieve a network of 80,000 warehouses in two years, as announced on April 26, 2023. The new 3,000 hectares of cultivated farming land is expected to generate an additional 6,000 Metric Tons of wheat per annum and an additional 16,000 Metric Tons of rice per annum with a combined market value of USD $17.5 million per annum. As the first of many other planned financing and production deals with AFAN, to be expanded to cover other crop types, the Company expects the arrangement to become a very significant source of supply into both the Tingo Foods processing business for onward supply of finished food and beverage products to domestic and international markets, and the Tingo DMCC business for direct export. Through AFAN's position as the umbrella body of all 56 recognized commodities and agricultural associations in Nigeria, today's extension and strengthening of the relationship between the parties is expected to be highly valuable for the overall Tingo group eco-system. AFAN's utilization of part of the facility to accelerate the onboarding of more warehouses to the Tingo Mobile, PCX and AFAN partnership is also expected to be very valuable to the Tingo group as additional warehouses not only strengthen Tingo Mobile's infrastructure, goods handling and logistics capabilities, they also expand Tingo Food's and Tingo DMCC's access to produce through the right of first refusal agreement over goods received into the warehouses.

08:32 EDT Neurocrine presents data from long term use of INGREZZA - Neurocrine Biosciences presented findings from a meta-analysis of three long-term studies evaluating INGREZZA capsules that demonstrated substantial and sustained improvements in tardive dyskinesia in adults with or without concomitant antipsychotic therapy. The data (Poster #4) were presented at 2023 Psych Congress Elevate in Las Vegas. The analysis of the three studies demonstrated that treatment with once-daily INGREZZA (40 mg or 80 mg) resulted in substantial and sustained TD improvement through week 48 as measured by the Abnormal Involuntary Movement Scale total score, with no meaningful differences between study completers taking antipsychotics at baseline and those who were not. Upon withdrawal of INGREZZA, both subgroups experienced a return toward baseline severity of TD symptoms, demonstrating the potentially persistent nature of TD, even in patients no longer taking antipsychotic therapy. Researchers concluded that continuous treatment with INGREZZA to manage TD may be warranted irrespective if they were on concurrent antipsychotic therapy.

08:32 EDT Bon Natural Life launches vegetable-based powdered drinks - Bon Natural Life announced the launch of three powder drinks to its cruciferous vegetable-based health supplement series. The new powder drinks include: broccoli seed caffeine powder drink, broccoli seed coconut powder drink, and broccoli seed green tea powder drink.

08:11 EDT Novartis says Kisqali reduced risk of breast cancer recurrence by 25% in study - Novartis presented "positive primary endpoint data" from the pivotal Phase 3 NATALEE trial at the 2023 American Society of Clinical Oncology, or ASCO, Annual Meeting. Data showed that Kisqali plus endocrine therapy, compared to ET alone, lowered the risk of cancer recurrence by 25.2% in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer along with "a consistent, clinically meaningful" invasive disease-free survival, or iDFS, benefit across key pre-specified subgroups, the company announced. Novartis plans to submit these Phase III data to regulatory authorities in the U.S. and Europe before end of year. "Patients diagnosed with HR+/HER2- early breast cancer remain at risk of cancer recurrence, given that one-third of patients diagnosed with stage II and more than half of those diagnosed with stage III will unfortunately experience a return of their cancer. The compelling data from NATALEE highlight the potential of Kisqali to reduce the risk of cancer recurrence in this at-risk population, including node-negative patients, while maintaining a favorable safety profile. These potentially practice-changing results reinforce the unique and well-established profile of Kisqali as a proven treatment in HR+/HER2- metastatic breast cancer," said Shreeram Aradhye, M.D., President, Global Drug Development and Chief Medical Officer, Novartis.

08:09 EDT Freshpet files preliminary proxy statement in connection with Annual Meeting - Freshpet filed its preliminary proxy statement with the Securities and Exchange Commission in connection with its upcoming Annual Meeting of Stockholders. The company said, "As part of Freshpet's continuing commitment to reach a resolution with JANA Partners that is in the best interest of all stockholders, the Company is offering to interview JANA's independent director nominees in light of the unplanned resignation of David Basto from the Board. This current offer follows the Company's extensive engagement with JANA over nearly 9 months and efforts to reach a constructive resolution to avoid a distracting proxy fight. The Board and management have engaged on more than a dozen occasions with JANA since it first disclosed its holdings on September 22, 2022 and have made multiple attempts to settle for independent Board nominees, each of which JANA rejected."

08:05 EDT Aspira Women's regained compliance with Nasdaq's min bid price requirement - Aspira Women's Health announced that it has received notification from the Listing Qualifications Department of the Nasdaq Stock Market that Aspira has regained compliance with the Nasdaq minimum bid price requirement, as is required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2), based on achieving the minimum closing bid price per share for 10 consecutive business days. The Notice also indicated that because the Company is now in compliance with the Bid Price Requirement, Nasdaq considers the matter closed.

08:04 EDT Seaport Global, American Battery Materials enter combination agreement - Seaport Global Acquisition II and American Battery Materials announced that they have entered into a definitive merger agreement for a business combination that will result in ABM becoming a wholly-owned subsidiary of SGII. The holders of outstanding ABM shares will receive equity in SGII valued at $160M. The Boards of Directors of both ABM and SGII have unanimously approved the Proposed Business Combination, which is subject to customary closing conditions, including receipt of all regulatory approvals, as well as the approval by ABM's and SGII's shareholders. The combined company is expected to be renamed "American Battery Materials Holdings", and its common stock and warrants are expected to be listed on the Nasdaq Global Market. ABM is an exploration stage company focused on DLE and other minerals critical to the global energy transition. The Company owns 102 federal mining claims in Eastern Utah across 2,040 acres of federal land including seven existing wells. ABM is focused on supplying domestically-sourced critical minerals, with a particular focus on lithium, to global markets. Capital raised from the transaction is expected to be used to invest further in the development of the Company's existing United States-based mining assets, in addition to exploring ways to broaden and further diversify the Company's portfolio of land assets across geographies. The combined company will have an estimated pro-forma enterprise value of $225M. It is intended that 100% of existing ABM shareholders will roll over their equity and own approximately 70% of the pro forma equity of the combined company in connection with the Proposed Business Combination, which is expected to close in the fourth quarter of 2023, subject to stockholder approvals and other customary closing conditions.

08:04 EDT Liminal BioSciences nominates LMNL6326 for OXER1 antagonist program - Liminal BioSciences announced that the company has nominated a lead preclinical candidate, LMNL6326, for the development of its OXER1 antagonist program, targeting the treatment of eosinophil-driven diseases. "We are pleased to be nominating LMNL6326 as our second preclinical candidate of 2023, strengthening our development pipeline and validating our G protein-coupled receptor drug discovery engine," stated Bruce Pritchard, CEO of Liminal BioSciences. "We are excited to be working on an antagonist for the OXER1 receptor, providing a significant opportunity in a large and growing global eosinophil-driven diseases market. We hope that LMNL6326 could be a potential product candidate for the treatment of eosinophil-driven diseases which may include eosinophilic asthma and atopic dermatitis."

08:02 EDT Pioneer Power's e-Boost mobile solution selected by major automaker - Pioneer Power Solutions announced that an autonomous driving division of a major global automaker has transacted for multiple e-Boost units to support the initial rollout of autonomous electric vehicles in several cities. Deliveries are expected to begin in September 2023 and be complete by the end of the current fiscal year. "This order further evidences how e-Boost is evolving into the solution of choice for rapid, mobile fast charging independent of any grid connection," added Nathan Mazurek, Pioneer Power's Chairman and CEO. "We expect that our e-Boost product offering will contribute between 5 to 10% to Pioneer's top-line during the current fiscal year and between 10 to 20% during the fiscal year ending December 31, 2024."

07:36 EDT Saia reports May LTL shipments per workday declined 4.2% - Saia is providing LTL shipment and tonnage data for the first two months of the second quarter. In April 2023, final LTL shipments per workday declined 5.7%, LTL tonnage per workday declined 1.1% and LTL weight per shipment increased 4.9% to 1,460 pounds compared to 1,392 pounds in April 2022. In May 2023, LTL shipments per workday declined 4.2%, LTL tonnage per workday declined 2.0% and LTL weight per shipment increased 2.3% to 1,453 pounds compared to 1,421 pounds in May 2022.

07:34 EDT Enstar Group completes loss portfolio transfer with RACQ - Enstar Group announced that one of its wholly-owned subsidiaries has closed a previously announced Loss Portfolio Transfer agreement with RACQ Insurance Limited to reinsure 80% of RACQ's motor vehicle compulsory third party insurance liabilities, covering accident years 2021 and prior. Under the reinsurance agreement, which is effective as of July 1, 2022, RACQ will cede net reserves of approximately AUD$ 360 million, and Enstar's subsidiary will provide approximately AUD$ 200 million of cover in excess of the ceded reserves. The amount of net loss reserves ceded, as well as the settlement and limit amounts provided in the agreement, will be adjusted for claims paid between the effective date and the closing date of the transaction, pursuant to the terms of the contract.

07:32 EDT CME Group reports May ADV growth of 3% - CME Group reported its May 2023 market statistics, showing average daily volume increased 3% to 25M contracts during the month, the highest May ADV in company history. Reference Link

07:17 EDT CareTrust REIT acquires 125-bed skilled nursing facility in Houston area - CareTrust REIT announced that it has acquired a 125-bed skilled nursing facility located in the greater Houston metropolitan area. The facility will be operated by an affiliate of Evergreen Health Group, a new tenant relationship for CareTrust. Evergreen Health Group is a Texas-based operator of skilled nursing facilities primarily owned by Selina Chao, a proven and experienced industry veteran. Evergreen, who took over operations on June 1 has entered into a 15-year NNN lease with CareTrust that includes two, five-year extension options and annual CPI-based rent escalators.

07:06 EDT Agrify releases new Diamond Miner product under Precision Extraction Solutions - Agrify Corporation announced the release of its new Diamond Miner product under solvent extraction brand Precision Extraction Solutions. The Diamond Miner is designed to deliver a safe, reliable, and consistent solution for THC-A crystallization of cannabis, enabling the creation of premium concentrates. With the release of the Diamond Miner, Precision can provide customers with a full suite of equipment for taking cannabis from biomass to concentrates. The Diamond Miner has an optimal capacity of 1.3 liters and eliminates the need for mason jars for added safety and consistency. Featuring a liquid jacketed vessel for consistent temperature control and repeatable results, the Diamond Miner maintains a consistent internal environment to tightly control the variation in temperature and pressure internally.

07:03 EDT Autolus Therapeutics presents results from Phase 2 FELIX study - Autolus Therapeutics announces the presentation of top-line data from the Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-cell Acute Lymphoblastic Leukemia, B-ALL, at the 2023 American Society of Clinical Oncology, ASCO, Annual Meeting. In the pivotal morphological cohort of the FELIX trial, 112 patients with r/r adult ALL were enrolled and 94 patients were dosed with obe-cel. Of the dosed patients, 76% patients achieved a complete response or CR with incomplete haematological recovery, and 97% of the responders with evaluable samples were in deep remission with no detectable minimal residual disease. Safety analysis demonstrated a potentially best-in-class tolerability profile with Grade greater than or equal to 3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in 3% (3/94) and 7% of patients, respectively. Most of the toxicity was seen in patients with high disease burden. Notably, 6 of 7 Grade greater than or equal to3 ICANS were observed among patients with very high tumor burden of more than 75% bone marrow blasts at lymphodepletion. Overall, Grade greater than or equal to3 adverse events occurred in 79% of patients, with neutropenia, and thrombocytopenia most commonly reported. "We are pleased that our pivotal FELIX study confirms the attractive product profile for obe-cel, combining a high level of clinical activity with an excellent safety profile which we know is critical for this highly pre-treated and frail patient population. Conducting this study through the pandemic was a pressure test for obe-cel's product profile and our ability to deliver obe-cel reliably under difficult circumstances. We would like to thank patients, their care givers, nurses and treating physicians for their participation in the FELIX study," said Dr. Christian Itin, Chief Executive Officer of Autolus.

07:02 EDT Acreage Holdings CEO Caldini to resign, Curran to succeed - Acreage (ACRHF) announced that Peter Caldini has elected to resign from his position as Chief Executive Officer, effective June 30, 2023. Dennis Curran, Chief Operating Officer of Acreage, has been appointed Chief Executive Officer and will assume the role on July 1, 2023. Curran joined Acreage in March 2022, bringing over 35 years of leadership expertise in sales, distribution, and marketing, having previously held executive-level positions with GSK Consumer Health (GSK)

06:47 EDT BioNTech, OncoC4 present 'positive' Phase 1/2 data for BNT316/ONC-392 - BioNTech and OncoC4 announced positive preliminary data from the ongoing Phase 1/2 trial with the companies' anti-CTLA-4 antibody candidate, BNT316/ONC-392, in a patient cohort with metastatic, PD-1-resistant non-small cell lung cancer. The preliminary results show encouraging clinical anti-tumor activity for BNT316/ONC-392 as a monotherapy in a hard-to-treat patient population, as well as a manageable safety profile. The data will be presented in a poster discussion session at the 2023 American Society of Clinical Oncology Annual Meeting by Kai He, M.D., Ph.D., Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, USA. The results featured at the ASCO Annual Meeting include a total of 27 patients with metastatic, PD-1-resistant NSCLC, available for tumor response assessment who have received at least two doses of 10 mg/kg of BNT316/ONC-392. At data cut-off, the overall response rate among evaluable patients was 29.6%, with a disease control rate of 70.4%, including 1 complete response, 7 partial responses and 11 patients with stable disease. BNT316/ONC-392 continues to be well tolerated with a manageable safety profile. Immune-related adverse events of Grade 3 and 4 were observed in 10 patients, which is considered lower than what was reported for similar drugs.

06:02 EDT Marathon Digital provides bitcoin production for May - Management commentary: "We produced a record 1,245 bitcoin in May, up 77% from last month and 366% from May 2022," said Fred Thiel, Marathon's chairman and CEO. "The increased production was due to an increased hash rate and a significant increase in transaction fees, which accounted for approximately 11.8% of the total bitcoin we earned in the last month. The emergence of Ordinals significantly increased transaction fees in May, which in some cases, were so high that they exceeded the 6.25 BTC block reward. With our scale and our improved uptime during the month, we were able to capitalize on this opportunity. While such abnormally high transaction fees are historically rare, we believe these events can serve as a positive sign for the future of mining economics. In May, we increased our operational hash rate 9% month-over-month to 15.2 exahashes, and we increased our installed hash rate 13% month-over-month to 20.1 exahashes. With the construction of Applied Digital's facility in Ellendale, ND progressing and optimizations across our fleet continuing, we believe we are on track to reach our 23 EH/s target near the middle of this year. Also in May, we announced that we were joining forces with Brink to raise up to $1 million to support Bitcoin Core developers. In less than four days, we collectively raised nearly $800,000 for Bitcoin Core developers, $500,000 of which is Marathon's contribution. We are incredibly grateful to the Bitcoin community for rallying behind this initiative to support the volunteers who maintain the open-source protocol on which we all depend. We encourage every Bitcoiner and Bitcoin-related company to support the Bitcoin Core developers and join us in closing the gap to raise $1 million for the Bitcoin Core developers."

05:05 EDT Vanda Pharmaceuticals receives Orphan Drug Designation for VCA-894A - Vanda Pharmaceuticals announced the FDA has granted Orphan Drug Designation for VCA-894A for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S, caused by cryptic splice site variants within IGHMBP2.